Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep-Oct;12(5):325-33.
doi: 10.1177/2325957413491432.

Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy

Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy

Katherine Krauskopf et al. J Int Assoc Provid AIDS Care. 2013 Sep-Oct.

Abstract

Background: It is unclear whether HIV-related factors modify risk of hypertension (HTN). In a cohort of patients with AIDS, the authors determined HTN incidence and prevalence and assessed associated traditional, HIV-specific, and retinal vasculature factors.

Methods: Prospective observational cohort included 2390 patients with AIDS (1998-2011). Univariate analysis was used to assess the impact of traditional- and AIDS-related risk factors for HTN prevalence and incidence. Multivariate regression analyses were used to evaluate the adjusted impact of these factors.

Results: Hypertension prevalence was 22%(95% confidence interval [CI] 21%-24%) and was associated with traditional HTN risk factors (age, black race, and higher weight) as well as diabetes, hyperlipidemia, time since AIDS diagnosis, and higher CD4 counts. Hypertension incidence was 64.1 per 1000 person-years (95% CI 58.7/1000-69.9/1000). Age, race, weight, and diabetes were associated with incident HTN but HIV-specific factors were not.

Conclusions: Hypertension, a prevalent cardiovascular risk factor in patients with AIDS, is associated with traditional and metabolic risk factors.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Dr. Jabs has been a consultant to Abbott Pharmaceuticals, Alcon Laboratories, Allergan, Inc., Corcept Therapeutics, Genentech, Genzyme Corporation, GlaxoSmithKline, and Roche Pharmaceuticals, and serves on Data and Safety Monitoring Committees for Applied Genetic Technologies Corporation and Novartis Pharmaceutical Corporation. The remaining authors have no conflicts of interest to declare.

Similar articles

Cited by

References

    1. Novoa AM, de Olalla PG, Clos R, Orcau A, Rodriguez-Sanz M, Cayla JA. Increase in the non-HIV-related deaths among AIDS cases in the HAART era. Curr HIV Res. 2008;6(1):77–81. - PubMed
    1. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006 Sep 19;145(6):397–406. - PubMed
    1. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011 Dec;53(11):1130–1139. - PubMed
    1. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010 May 15;50(10):1387–1396. - PMC - PubMed
    1. Palella FJ, Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006 Sep;43(1):27–34. - PubMed

Publication types